TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26369660

Group type: EXPERIMENTAL
Intervention: Magnetic wire navigation (MWN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 40
Study: 24750798

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite coated screws
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard screws
Number of subjects: 54
Study: 22830646

Group type: EXPERIMENTAL
Intervention: Lunchtime walking intervention in an urban environment, twice a week for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lunchtime walking intervention in a natural environment, twice a week for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-selected walking routes during lunch breaks in phase 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometer monitoring of physical activity
Number of subjects: 0
Study: 20932208

Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: iCBT+MS
Number of subjects: 108
Study: 18533183

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg mCPP with ritanserin pre-treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: mCPP administration
Number of subjects: 20
Study: 15674303

Group type: EXPERIMENTAL
Intervention: 0.25 g WA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5 g WA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.0 g WA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5 g WA (long-term administration)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0 g WA (control for long-term administration)
Number of subjects: 36
Study: 12083587

Group type: EXPERIMENTAL
Intervention: IV parecoxib sodium 40 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: morphine 4 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: ketorolac 30 mg
Number of subjects: 208

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 208
Study: 10099995

Group type: EXPERIMENTAL
Intervention: 5% O2
Number of subjects: 1380

Group type: COMPARATOR
Intervention: 20% O2
Number of subjects: 1380
Study: 8924965

Group type: EXPERIMENTAL
Intervention: HA-1A
Number of subjects: 131
Study: 2150677

Group type: EXPERIMENTAL
Intervention: Thermafil obturation technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lateral condensation
Number of subjects: 80
Study: 348229

Group type: EXPERIMENTAL
Intervention: Cephaloridine (3 doses of 1 g each: 1 g IV at surgery start, 1 g IM at 6 hours, 1 g IM at 12 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cephaloridine (3 doses of 1 g each)
Number of subjects: 100
Study: 31150497

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26768233

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary counselling twice by telephone and access to twice‐weekly exercise groups)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Standard prenatal care (control group)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 606

Group type: COMPARATOR
Intervention: Lifestyle intervention and control
Number of subjects: 606
Study: 27411014

Group type: EXPERIMENTAL
Intervention: Prednisolone (glucocorticoid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (in vitro)
Number of subjects: 0
Study: 25741842

Group type: EXPERIMENTAL
Intervention: 500 ml HES 130/0.4
Number of subjects: 105

Group type: COMPARATOR
Intervention: 1500 ml 9‰ saline solution
Number of subjects: 105
Study: 22577064

Group type: EXPERIMENTAL
Intervention: 6MWT (Six-Minute Walk Test) performed at home
Number of subjects: 173

Group type: COMPARATOR
Intervention: Single 6MWT performed at weeks 8 and 26
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: SF-36 PF score
Number of subjects: 173
Study: 20955443

Group type: EXPERIMENTAL
Intervention: etoricoxib
Number of subjects: 34701

Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: not available
Number of subjects: 34701
Study: 19022992

Group type: EXPERIMENTAL
Intervention: Post-vasectomy group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 16091706

Group type: EXPERIMENTAL
Intervention: F‐milk (daily approx. 0.2 l with the level 2.5 ppm)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: F‐milk
Number of subjects: 510
Study: 12585183

Group type: EXPERIMENTAL
Intervention: Mifepristone and Chinese herbal medicine (CHM)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Methotrexate and Chinese herbal medicine (CHM)
Number of subjects: 114
Study: 10941859

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) 1.2 ml injected endoscopically
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline 1.2 ml injected endoscopically (Control)
Number of subjects: 5
Study: 8749123

Group type: EXPERIMENTAL
Intervention: Low dose ethanol (0.45 g/kg LBW)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Medium dose ethanol (0.80 g/kg LBW)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High dose ethanol (1.05 g/kg LBW)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 1331632

Group type: EXPERIMENTAL
Intervention: Physician-led primary home care and home assistance service on a 24-hour basis
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 249
Study: 4061105

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg four times daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol 60 mg four times daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and propranolol (90 mg and 60 mg respectively, both four times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31355878

Group type: EXPERIMENTAL
Intervention: Intensive BP control (target BP < 120/80 mm Hg)
Number of subjects: 1263

Group type: COMPARATOR
Intervention: Standard BP control (target BP < 140/90 mm Hg)
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Meta-analysis of intensive BP control
Number of subjects: 1263
Study: 30505414

Group type: EXPERIMENTAL
Intervention: Surgical-site injections (SIs) with a mixture of epinephrine hydrochloride, morphine sulfate, ropivacaine HCL, and normal saline.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surgical-site injections (SIs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No surgical-site injections (no-SI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgical-site injections (SIs) and no-SI
Number of subjects: 50
Study: 26693818

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Pharmacotherapy with spironolactone addition
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Complete RDN
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Spironolactone addition
Number of subjects: 106
Study: 24359050

Group type: EXPERIMENTAL
Intervention: Intramuscular dexketoprofen trometamol with paracervical block
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intramuscular dexketoprofen trometamol without paracervical block
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intracavitary lidocaine instillation with paracervical block
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intracavitary lidocaine instillation without paracervical block
Number of subjects: 120
Study: 23715650

Group type: EXPERIMENTAL
Intervention: Pringle manoeuvre
Number of subjects: 252

Group type: COMPARATOR
Intervention: Hemi-hepatic vascular inflow occlusion
Number of subjects: 252
Study: 21242684

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy with overhydration value (OH) revealed to patients and nurses
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard methods without revealing OH values
Number of subjects: 160
Study: 19723992

Group type: EXPERIMENTAL
Intervention: Femoral tunnel in the eleven o'clock position
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Femoral tunnel in the ten o'clock position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 17604559

Group type: EXPERIMENTAL
Intervention: Active biofeedback
Number of subjects: 38
Study: 15208157

Group type: EXPERIMENTAL
Intervention: Ethanol (0.45 g/kg b.w.) with placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ethanol (0.45 g/kg b.w.) with propranolol (40 mg at 08:00 and 20 mg at 12:00)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Alcohol ingestion
Number of subjects: 7
Study: 11998300

Group type: EXPERIMENTAL
Intervention: Audio alarm
Number of subjects: 47

Group type: COMPARATOR
Intervention: Vibration alarm
Number of subjects: 47
Study: 9602954

Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg daily for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Caffeine (100 mg)
Number of subjects: 12
Study: 8640469

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) used on mothers during perinatal period
Number of subjects: 8
Study: 2264190

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7016928

Group type: EXPERIMENTAL
Intervention: guanabenz plus hydrochlorothiazide
Number of subjects: 52

Group type: COMPARATOR
Intervention: guanabenz plus placebo
Number of subjects: 52
Study: 31506757

Group type: EXPERIMENTAL
Intervention: Dysregulated sleep
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Higher levels of dysregulated sleep
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: More severe internalizing problems
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Visit-specific elevations in dysregulated sleep
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Visit-specific elevations in anxiety and depression severity
Number of subjects: 319
Study: 31677537

Group type: EXPERIMENTAL
Intervention: Early Norepinephrine (NEP) with IV fluids
Number of subjects: 101

Group type: COMPARATOR
Intervention: Late Norepinephrine (NEP) after failed fluids trial
Number of subjects: 101
Study: 28732546

Group type: EXPERIMENTAL
Intervention: Sodium-restriction educational intervention group (60 participants)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care control group (60 participants)
Number of subjects: 120
Study: 26374231

Group type: EXPERIMENTAL
Intervention: COSMOS intervention (2-day education program including written guidelines, repeated theoretical and practical training, case discussions, and role play)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Current best practice (control group)
Number of subjects: 571
Study: 23586852

Group type: EXPERIMENTAL
Intervention: Robot intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: Human trainer intervention
Number of subjects: 6
Study: 21162685

Group type: EXPERIMENTAL
Intervention: Low-iodine diet for 2 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-iodine diet for 3 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both diets (2 weeks and 3 weeks)
Number of subjects: 46
Study: 19395396

Group type: EXPERIMENTAL
Intervention: 12-session standardised curriculum ('Unplugged')
Number of subjects: 6359

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6359
Study: 17198072

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic liver biopsy
Number of subjects: 857

Group type: COMPARATOR
Intervention: Percutaneous liver biopsy
Number of subjects: 857
Study: 15025403

Group type: EXPERIMENTAL
Intervention: TNX-901 (450 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TNX-901 (150 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TNX-901 (300 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 11242179

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (80 mg of trimethoprim and 400 mg of sulphamethoxazole daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9745421

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg (diet-only subset)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg (sulfonylurea subset)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg (sulfonylurea subset)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg (sulfonylurea subset)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg and 600 mg
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 7828971

Group type: EXPERIMENTAL
Intervention: 1.9 mm inner, 2.9 mm (9F) outer diameter Fresenius tube
Number of subjects: 76

Group type: COMPARATOR
Intervention: 3.0 mm inner, 4.0 mm (12F) outer diameter Bower polyurethane tube
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: PEG feeding
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: PEG procedure
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nursing time for PEG care
Number of subjects: 76
Study: 2109465

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 mg i.v.)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 128
Study: 6994518

Group type: EXPERIMENTAL
Intervention: Levallorphan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiphenazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 0
Study: 31669449

Group type: EXPERIMENTAL
Intervention: Hybrid clinical trial design integrating traditional randomized controlled trial with pragmatic design aspects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid designs in vaccine development
Number of subjects: 0
Study: 31513232

Group type: EXPERIMENTAL
Intervention: Opioid use in North America
Number of subjects: 9670
Study: 28385433

Group type: EXPERIMENTAL
Intervention: Simplified edentulous treatment (SET)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 64
Study: 25609193

Group type: EXPERIMENTAL
Intervention: Trelagliptin (100 mg once per week)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Alogliptin (25 mg once per day)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 23896675

Group type: EXPERIMENTAL
Intervention: Integrated clinical prediction rule tool
Number of subjects: 0
Study: 21366599

Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy (three times a week for 2 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fexofenadine HCl (180 mg per day for 2 weeks)
Number of subjects: 31
Study: 19711095

Group type: EXPERIMENTAL
Intervention: Combined nebulized bronchodilators (BD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 17366346

Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 24
Study: 14644068

Group type: EXPERIMENTAL
Intervention: 0.5 mg of dexamethasone (DEX)
Number of subjects: 62
Study: 11443153

Group type: EXPERIMENTAL
Intervention: GH (genotropin 4 IU/m(2).day) and GnRHa (triptorelin, 3.75 mg/28 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 36
Study: 9610711

Group type: COMPARATOR
Intervention: Doxorubicin (n=106)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Epirubicin (n=105)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both Doxorubicin and Epirubicin
Number of subjects: 211
Study: 8148931

Group type: EXPERIMENTAL
Intervention: 15 mg dexfenfluramine (DF) twice daily
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 20 mg/200 mg ephedrine/caffeine (EC) three times a day
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Subgroup of patients with BMI >= 30 kg/m2 on DF
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Subgroup of patients with BMI >= 30 kg/m2 on EC
Number of subjects: 103

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 103
Study: 3491942

Group type: EXPERIMENTAL
Intervention: Actual electrical stimulation with Audimax Theraband
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 30
Study: 31328607

Group type: EXPERIMENTAL
Intervention: Manual-based personalized intervention for mothers
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (untrained mothers)
Number of subjects: 73
Study: 29246819

Group type: EXPERIMENTAL
Intervention: Self-reported contraceptive use (no hormonal contraceptive use in the previous 6 months)
Number of subjects: 97
Study: 26829646

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Psychoanalysis (PA)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Short-term therapy
Number of subjects: 367
Study: 26148362

Group type: EXPERIMENTAL
Intervention: Desflurane-based anesthesia
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sevoflurane-based anesthesia
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Desflurane-based anesthesia with fentanyl
Number of subjects: 125
Study: 23402525

Group type: EXPERIMENTAL
Intervention: Minimal Psychological Intervention (MPI) administered by trained nurses in cognitive behavioural therapy and self-management.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 124
Study: 21400388

Group type: EXPERIMENTAL
Intervention: Transfer, Lifting and Repositioning (TLR) program
Number of subjects: 766

Group type: COMPARATOR
Intervention: Control group (no TLR program)
Number of subjects: 766
Study: 18784526

Group type: EXPERIMENTAL
Intervention: 0.5% sterile solution of metronidazole (2 mL, 10 mg) incorporated in the sinus bone graft
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no metronidazole)
Number of subjects: 72
Study: 16898076

Group type: EXPERIMENTAL
Intervention: New retard tablet formulation (240mg oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard retard tablet formulation (240mg oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous dose (5mg)
Number of subjects: 12
Study: 14597782

Group type: EXPERIMENTAL
Intervention: Epidural morphine (3 mg in 10 ml saline)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (10 ml saline)
Number of subjects: 48
Study: 11070572

Group type: EXPERIMENTAL
Intervention: Mebeverine hydrochloride 135 mg t.i.d. (Colofac)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Mebeverine hydrochloride 200 mg b.i.d. (Colofac MR)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 213
Study: 8612411

Group type: EXPERIMENTAL
Intervention: Monitor group (n = 10) with end-tidal CO2 monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: No-monitor group (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Monitor-blind group (n = 25)
Number of subjects: 50
Study: 1450803

Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection (methylprednisolone and lignocaine)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo injection (lignocaine alone)
Number of subjects: 11
Study: 6363095

Group type: EXPERIMENTAL
Intervention: 90 mg of MA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 180 mg of MA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 270 mg of MA
Number of subjects: 18
Study: 31019730

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 124

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study: 29094178

Group type: EXPERIMENTAL
Intervention: UFT + PSK
Number of subjects: 111

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 111
Study: 26884559

Group type: EXPERIMENTAL
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by ifosfamide-containing salvage treatment and stem-cell transplantation for PET2-positive patients
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for PET2-negative patients
Number of subjects: 519
Study: 24771373

Group type: EXPERIMENTAL
Intervention: Emoxipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-hydroxypyridine derivatives (emoxipine and mexidol)
Number of subjects: 0
Study: 22234614

Group type: EXPERIMENTAL
Intervention: Nonreinforced X‐‐ B‐ presentations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonreinforced X‐‐ B‐ trials
Number of subjects: 0
Study: 20871804

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy in home care (PST-HC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care plus education intervention (Control)
Number of subjects: 38
Study: 17617743

Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib vaccine administered at 0, 4, and 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib vaccine
Number of subjects: 0
Study: 16344017

Group type: EXPERIMENTAL
Intervention: Standardized rehabilitation and discharge planning
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control (no standardized rehabilitation and discharge planning)
Number of subjects: 919
Study: 12051400

Group type: EXPERIMENTAL
Intervention: MTX treated RA patients
Number of subjects: 119

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: MTX treated RA patients with folic acid supplementation
Number of subjects: 119
Study: 10658409

Group type: EXPERIMENTAL
Intervention: 25 gauge open-end pencil point spinal needle
Number of subjects: 24

Group type: COMPARATOR
Intervention: 25 gauge Quincke needle
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 8654899

Group type: EXPERIMENTAL
Intervention: Ineraid cochlear implant users
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nucleus cochlear implant users
Number of subjects: 41
Study: 2162274

Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium protein meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low protein meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbohydrate control meal
Number of subjects: 0